Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4668327 | 0.94 | SMN1; SMN2 (0.56) | SMN1; SMN2HSD11B1ALDH1A1KDM4EHPGD | |
| SCHEMBL4668202 | 0.83 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1KDM4EGAAMAPT | |
| SCHEMBL28735731 | 0.80 | HPGD (0.63) | SMN1; SMN2ALDH1A1KDM4EHPGDTSHR | |
| SCHEMBL20521101 | 0.80 | HPGD (0.63) | SMN1; SMN2ALDH1A1KDM4EHPGDTSHR | |
| SCHEMBL4667221 | 0.78 | HSD11B1 (0.66) | SMN1; SMN2HSD11B1ALDH1A1KDM4ETSHR | |
| SCHEMBL27217441 | 0.77 | THRB (0.41) | SMN1; SMN2KDM4EGAAMAPTKMT2A | |
| SCHEMBL4321783 | 0.77 | CHRM5 (0.48) | SMN1; SMN2GAAMAPTLMNA | |
| SCHEMBL3825062 | 0.77 | SMN1; SMN2 (0.44) | SMN1; SMN2ALDH1A1KDM4EGAAHTT | |
| SCHEMBL3165975 | 0.75 | CHRM5 (0.57) | SMN1; SMN2GAAMAPTLMNA | |
| SCHEMBL4666619 | 0.75 | SMN1; SMN2 (0.51) | SMN1; SMN2HSD11B1ALDH1A1HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1802307-B1 | PYRROLIDINE DERIVATIVES AS HISTAMINE RECEPTORS LIGANDS | GLAXO GROUP LTD (GB) | 2008-02-27 | — | — | EP | disclosed |
| US-20080045506-A1 | Pyrrolidine Derivatives as Histamine Receptors Ligands | GLAXO GROUP LIMITED (GB) | 2008-02-21 | — | — | US | disclosed |
| EP-1802307-A1 | PYRROLIDINE DERIVATIVES AS HISTAMINE RECEPTORS LIGANDS | GLAXO GROUP LIMITED (GB) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006040192-A1 | PYRROLIDINE DERIVATIVES AS HISTAMINE RECEPTORS LIGANDS | GLAXO GROUP LIMITED (GB) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045506-A1 | Pyrrolidine Derivatives as Histamine Receptors Ligands | HRH4, HRH3, HRH2 | SMN1; SMN2 3501/4885HSD11B1 3368/4885ALDH1A1 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.